CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Breast Neoplasms
Carboplatin
Female
Humans
Neoadjuvant Therapy
Neoplasm, Residual
Paclitaxel
Triple Negative Breast Neoplasms

authors with profiles

Olwen Hahn
Mei-Yin Polley